Stepwise Application of Urine Markers to Detect Tumor Recurrence in Patients Undergoing Surveillance for Non-Muscle-Invasive Bladder Cancer

Disease Markers

Volumn 2014, Issue , 2014, Pages

  Todenhöfer, Tilman ^a,b   Hennenlotter, Jörg ^a   Esser, Michael ^a   Mohrhardt, Sarah ^a   Aufderklamm, Stefan ^a   Böttge, Johannes ^a   Rausch, Steffen ^a   Mischinger, Johannes ^a   Bier, Simone ^a   Gakis, Georgios ^a   Kuehs, Ursula ^a   Stenzl, Arnulf ^a   Schwentner, Christian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEAR MATRIX PROTEIN 22; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER DETECTION KIT; CANCER DIAGNOSIS; CANCER STAGING; CARCINOMA IN SITU; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; IMMUNOCYTOLOGY TEST; IMMUNOLOGY TEST KIT; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; PREDICTIVE VALUE; PROBABILITY; PROTEIN URINE LEVEL; TUMOR RECURRENCE; URINALYSIS; URINE CYTOLOGY; VERY ELDERLY; BLADDER TUMOR; DIAGNOSIS; MIDDLE AGED; PATHOLOGY; SENSITIVITY AND SPECIFICITY; URINE;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS;

EID: 84920532468     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2014/973406     Document Type: Article

References (26)

1. E. Xylinas, M. Kent, L. Kluth et al., "Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder, " British Journal of Cancer, vol. 109, no. 6, pp. 1460-1466, 2013.
2. J. A. Witjes, E. Compérat, N. C. Cowan et al., "EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines, " European Urology, vol. 65, no. 4, pp. 778- 792, 2014.
3. B. W. G. van Rhijn, M. Burger, Y. Lotan et al., "Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy, " European Urology, vol. 56, no. 3, pp. 430-442, 2009.
4. D. Schrag, L. J. Hsieh, F. Rabbani, P. B. Bach, H. Herr, and C. B. Begg, "Adherence to surveillance among patients with superficial bladder cancer, " Journal of the National Cancer Institute, vol. 95, no. 8, pp. 588-597, 2003.
5. H. B. Grossman, M. Soloway, E.Messing et al., "Surveillance for recurrent bladder cancer using a point-of-care proteomic assay, " The Journal of the AmericanMedical Association, vol. 295, no. 3, pp. 299-305, 2006.
6. C.Mian, K.Maier, E. Comploj et al., "uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma, " Cancer, vol. 108, no. 1, pp. 60-65, 2006.
7. P. S. Sullivan, F. Nooraie, H. Sanchez et al., "Comparison of ImmunoCyt, UroVysion, and urine cytology in detection of recurrent urothelial carcinoma: a "split-sample" study, " Cancer Cytopathology, vol. 117, no. 3, pp. 167-173, 2009.
8. A. M. Kamat, P. K. Hegarty, J. R. Gee et al., "ICUD-EAU international consultation on bladder cancer 2012: screening, diagnosis, and molecular markers, " European Urology, vol. 63, no. 1, pp. 4-15, 2013.
9. B. J. Schmitz-Drager, T. Todenhofer, B. van Rhijn et al., "Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer, " Urologic Oncology, vol. 32, no. 7, pp. 1061-1068, 2014.
10. T. Todenhöfer, J. Hennenlotter, V. Tews et al., "Impact of different grades of microscopic hematuria on the performance of urine-based markers for the detection of urothelial carcinoma, " Urologic Oncology: Seminars and Original Investigations, vol. 31, no. 7, pp. 1148-1154, 2013.
11. L. J. Layfield, T. M. Elsheikh, A. Fili, R. Nayar, and V. Shidham, "Review of the state of the art and recommendations of the Papanicolaou Society of Cytopathology for urinary cytology procedures and reporting: the Papanicolaou Society of Cytopathology Practice Guidelines Task Force, " Diagnostic Cytopathology, vol. 30, no. 1, pp. 24-30, 2004.
12. P. Riesz, G. Lotz, C. Páska et al., "Detection of bladder cancer from the urine using fluorescence in situ hybridization technique, " Pathology & Oncology Research, vol. 13, no. 3, pp. 187- 194, 2007.
13. I. A. Sokolova, K. C. Halling, R. B. Jenkins et al., "The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in Urine, " Journal of Molecular Diagnostics, vol. 2, no. 3, pp. 116- 123, 2000.
14. C. Mian, A. Pycha, H. Wiener, A. Haitel, M. Lodde, and M. Marberger, "Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract, "The Journal of Urology, vol. 161, no. 5, pp. 1486-1489, 1999.
15. K. L. Greene, A. Berry, and B. R. Konety, "Diagnostic utility of the immunoCyt/uCyt+ test in bladder cancer, " Reviews in Urology, vol. 8, pp. 190-197, 2006.
16. S. F. Shariat, M. J. Marberger, Y. Lotan et al., "Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer, " Journal of Urology, vol. 176, no. 3, pp. 919-926, 2006.
17. V. Soukup, M. Babjuk, J. Bellmunt et al., "Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature, " European Urology, vol. 62, no. 2, pp. 290-302, 2012.
18. J. A. Witjes, J. P. Redorta, D. Jacqmin et al., "Hexaminolevulinate- guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations, " European Urology, vol. 57, no. 4, pp. 607-614, 2010.
19. J. Palou Redorta, S. Skrobot, and G. Luccarelli, "372 Ultrasonography and cytology in the follow up of grade 1 nonmuscle invasive bladder cancer (NMIBC), " European Urology Supplements, vol. 12, no. 1, p. e372, 2013.
20. S. Gudjonsson, B. L. Isfoss, K. Hansson et al., "The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer, " European Urology, vol. 54, no. 2, pp. 402-408, 2008.
21. P.M. J.Moonen, G. F. M. Merkx, P. Peelen, H. F. M. Karthaus, D. F. C. M. Smeets, and J. A.Witjes, "UroVysion compared with cytology and quantitative cytology in the surveillance of nonmuscle- invasive bladder cancer, " European Urology, vol. 51, no. 5, pp. 1275-1280, 2007.
22. M. Lodde, C.Mian, E. Comploj et al., "uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma, " Urology, vol. 67, no. 5, pp. 950-954, 2006.
23. N. P. Gupta, N. Sharma, and R. Kumar, "Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder, " Urology, vol. 73, no. 3, pp. 592-597, 2009.
24. C. T. Nguyen and J. S. Jones, "Defining the role of NMP22 in bladder cancer surveillance, " World Journal of Urology, vol. 26, no. 1, pp. 51-58, 2008.
25. T. Zellweger, G. Benz, G. Cathomas et al., "Multi-target fluorescence in situ hybridization in bladderwashings for prediction of recurrent bladder cancer, " International Journal of Cancer, vol. 119, no. 7, pp. 1660-1665, 2006.
26. A. M. Kamat, J. A. Karam, H. B. Grossman, A. K. Kader, M. Munsell, and C. P. Dinney, "Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity, " BJU International, vol. 108, no. 7, pp. 1119-1123, 2011.